These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15050497)

  • 21. The effect of preinfarction angina on clinical reperfusion time in patients with acute myocardial infarction receiving successful thrombolytic therapy.
    Evrengul H; Celek T; Tanriverdi H; Kaftan A; Dursunoglu D; Kilic M
    Can J Cardiol; 2005 Sep; 21(11):915-20. PubMed ID: 16239974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Thrombolytic treatment of acute myocardial infarct. 1].
    Soares-Costa JT; Soares-Costa TJ; Gabriel HM
    Acta Med Port; 1998 May; 11(5):409-19. PubMed ID: 9951051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repeat thrombolysis for acute myocardial infarction.
    Banerjee P; Clark AL; Norell MS
    Int J Cardiol; 2005 Jul; 102(3):515-9. PubMed ID: 16004899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Repeat thrombolysis in acute myocardial infarction].
    Sychra M
    Vnitr Lek; 2002 Aug; 48(8):791-3. PubMed ID: 12425212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ASSENT-3: implications for future trial design and clinical practice.
    Van de Werf F
    Eur Heart J; 2002 Jun; 23(12):911-2. PubMed ID: 12069439
    [No Abstract]   [Full Text] [Related]  

  • 26. Optimizing outcomes in ST-segment elevation myocardial infarction.
    Herrmann HC
    J Am Coll Cardiol; 2003 Oct; 42(8):1357-9. PubMed ID: 14563574
    [No Abstract]   [Full Text] [Related]  

  • 27. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy.
    Ray KK; Morrow DA; Gibson CM; Murphy S; Antman EM; Braunwald E
    Eur Heart J; 2005 Mar; 26(5):440-6. PubMed ID: 15673542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Percutaneous coronary intervention versus thrombolysis: the definite management of st elevation myocardial infarction.
    Martinez-Ojeda J; Martinez-Toro J
    Bol Asoc Med P R; 2005; 97(4):308-14. PubMed ID: 16599071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rescue percutaneous coronary intervention after failed thrombolysis: results from the Acute Coronary Syndrome Israel Surveys (ACSIS).
    Yalonetsky S; Gruberg L; Sandach A; Hammerman H; Beyar R; Hod H; Behar S
    Acute Card Care; 2006; 8(2):83-6. PubMed ID: 16885071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tirofiban in acute coronary syndromes.
    Menozzi A; Merlini PA; Ardissino D
    Expert Rev Cardiovasc Ther; 2005 Mar; 3(2):193-206. PubMed ID: 15853593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Thrombolytic therapy for acute myocardial infarct].
    Nordt TK; Bode C
    Internist (Berl); 2001 May; 42(5):659-64. PubMed ID: 11400573
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of tirofiban on ST segment resolution in patients with non-ST elevated myocardial infarction.
    Bayturan O; Bilge AR; Seküri C; Utük O; Tikiz H; Eser E; Tezcan UK
    Jpn Heart J; 2004 Nov; 45(6):913-20. PubMed ID: 15655266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defining optimal therapy for the thrombolysis-ineligible patient.
    Cohen M
    Clin Cardiol; 2002 Nov; 25(11 Suppl 1):I23-6. PubMed ID: 12428816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin?
    Serebruany VL; Gurbel PA
    Thromb Haemost; 1999 Feb; 81(2):314-6. PubMed ID: 10064014
    [No Abstract]   [Full Text] [Related]  

  • 36. Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy.
    Januzzi JL; Sabatine MS; Wan Y; Servoss SJ; DiBattiste PM; Jang Ik; Theroux P
    Am J Cardiol; 2003 Feb; 91(4):457-61. PubMed ID: 12586266
    [No Abstract]   [Full Text] [Related]  

  • 37. Continuous tenecteplase infusion combined with peri/postprocedural platelet glycoprotein IIb/IIIa inhibition in peripheral arterial thrombolysis: initial safety and feasibility experience.
    Allie DE; Hebert CJ; Lirtzman MD; Wyatt CH; Keller VA; Khan MH; Khan MA; Fail PS; Stagg SJ; Chaisson GA; Vitrella DA; Allie SD; Allie AA; Mitran EV; Walker CM
    J Endovasc Ther; 2004 Aug; 11(4):427-35. PubMed ID: 15298512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Thrombolysis in acute myocardial infarction].
    Rutsch W
    Dtsch Med Wochenschr; 1994 Sep; 119(36):1220-1. PubMed ID: 8082591
    [No Abstract]   [Full Text] [Related]  

  • 39. Acute myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor.
    Gül C; Kürüm T; Demir M; Ozbay G; Vural O; Iqbal O; Fareed J
    Clin Appl Thromb Hemost; 2004 Jan; 10(1):77-9. PubMed ID: 14979411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vertebrobasilar thrombolysis with intravenous tirofiban: case report.
    Liebeskind DS; Pollard JR; Schwartz ED; Cucchiara BL; McGarvey ML; Hurst RW
    J Thromb Thrombolysis; 2002 Apr; 13(2):81-4. PubMed ID: 12101384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.